TRML - NASDAQ

Tourmaline Bio, Inc.

Tourmaline Bio, Inc.

TRML·NASDAQ

$47.98

+0.0000%
HealthcareBiotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.23B
EPS-2.8900
P/E Ratio-7.02
Earnings Date04/30/2026
-29.86%
Return on Invested Capital
35%
3Y-97.0%
5Y-36.0%
10Y-36.0%
-24.40%
Return on Equity
19%
3Y+6099675.0%
5Y-47.0%
10Y-47.0%
-23.69%
Return on Assets
18%
3Y+3831.0%
5Y-45.0%
10Y-45.0%
Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Management Team

TRML · NASDAQ
MW

Mr. W. Bradford Middlekauff J.D.

Chief Business Officer, General Counsel & Corporate Secretary

Compensation

$582,250

Born 1962(Age 64)
male
MR

Mr. Ryan Robinson CPA

Chief Financial Officer & Treasurer

Compensation

$575,855

Born 1989(Age 37)
male
DK

Dr. Kevin B. Johnson M.B.A., Ph.D.

Chief Regulatory Officer

Compensation

$555,835

Born 1965(Age 61)
DS

Dr. Susan Dana Jones Ph.D.

Chief Technology Officer

Born 1961(Age 65)
DS

Dr. Sandeep C. Kulkarni M.D.

Co-Founder, Chief Executive Officer & Director

Compensation

$848,250

Born 1982(Age 44)
MD

Ms. Dora Rau

Senior Vice President & Head of Quality

female
MG

Mr. Gerhard Hagn Pharm.D.

Senior Vice President and Head of Commercial & Business Development

male
DE

Dr. Emil M. deGoma M.D.

Senior Vice President of Medical Research

DK

Dr. Kristine Erickson O.D., Ph.D.

Vice President & TA Head of Ophthalmology, Medical Research

MK

Ms. Kimberly Piorkowski

Vice President of People, Culture & Compliance

female
trml

Tourmaline Bio, Inc. Insider Positioning

TRML · NASDAQ

During the last 12 months, insiders have sold $371K worth of TRML shares, with no buying activity reported.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

0

0.00

Sold

20.0K

371.00K

Net Activity

-371K

-$371K

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

No buying activity

Top Sellers

1
SCB

Siegall Clay B

Director

20.0K shares•1 transactions

$371K

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $371K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.00:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Insider Participation

High Selling

1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.

SEC Filings

TRML - Filing history and reports

No SEC filings available for TRML

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.